AxoGen, Inc. (NASDAQ:AXGN)’s share price reached a new 52-week high during trading on Friday . The stock traded as high as $30.45 and last traded at $28.65, with a volume of 398000 shares changing hands. The stock had previously closed at $28.15.
Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of AxoGen in a report on Friday. Jefferies Group assumed coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 price objective for the company. Leerink Swann lifted their price objective on shares of AxoGen from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, November 21st. Lake Street Capital lifted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Finally, Wedbush reaffirmed a “buy” rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.17.
The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. The firm has a market cap of $976.79, a P/E ratio of -77.63 and a beta of 0.40.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million during the quarter, compared to analyst estimates of $15.55 million. The business’s revenue was up 43.2% on a year-over-year basis. equities research analysts anticipate that AxoGen, Inc. will post -0.31 EPS for the current year.
In other AxoGen news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $19.74, for a total transaction of $22,701,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jamie Mark Grooms sold 21,290 shares of the business’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,293,990 shares of company stock valued at $26,494,898. 9.33% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in AXGN. Schwab Charles Investment Management Inc. lifted its position in AxoGen by 33.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 51,300 shares of the medical equipment provider’s stock worth $860,000 after acquiring an additional 13,000 shares during the last quarter. Rhumbline Advisers lifted its position in AxoGen by 11.4% during the 2nd quarter. Rhumbline Advisers now owns 28,720 shares of the medical equipment provider’s stock worth $481,000 after acquiring an additional 2,945 shares during the last quarter. Bank of New York Mellon Corp lifted its position in AxoGen by 80.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 160,354 shares of the medical equipment provider’s stock worth $2,685,000 after acquiring an additional 71,609 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in AxoGen during the 2nd quarter worth $201,000. Finally, Wells Fargo & Company MN lifted its position in AxoGen by 17.2% during the 2nd quarter. Wells Fargo & Company MN now owns 46,745 shares of the medical equipment provider’s stock worth $783,000 after acquiring an additional 6,848 shares during the last quarter. 66.00% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was posted by Equities Focus and is the property of of Equities Focus. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.equitiesfocus.com/2018/01/07/axogen-axgn-reaches-new-1-year-high-at-30-45.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.